Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury

Meghan O. Blaya, Joseph M. Wasserman, Andrew A. Pieper, Thomas J. Sick, Helen Bramlett, W. Dalton Dietrich

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a significant public health problem around the world. A promising area of research is the characterization of small, drug-like molecules that have potent clinical properties. One pharmacotherapeutic agent in particular, an aminopropyl carbazole called P7C3, was discovered using an in vivo screen to identify new agents that augmented the net magnitude of adult hippocampal neurogenesis. P7C3 greatly enhanced neurogenesis by virtue of increasing survival rates of immature neurons. The potent neuroprotective efficacy of P7C3 is likely due to enhanced nicotinamide phosphoribosyltransferase (NAMPT) activity, which supports critical cellular processes. The scaffold of P7C3 was found to have favorable pharmacokinetic properties, good bioavailability, and was nontoxic. Preclinical studies have shown that administration of the P7C3-series of neuroprotective compounds after TBI can rescue and reverse detrimental cellular events leading to improved functional recovery. In several TBI models and across multiple species, P7C3 and its analogues have produced significant neuroprotection, axonal preservation, robust increases in the net magnitude of adult neurogenesis, protection from injury-induced LTP deficits, and improvement in neurological functioning. This review will elucidate the exciting and diverse therapeutic findings of P7C3 administration in the presence of a complex and multifactorial set of cellular and molecular challenges brought forth by experimental TBI. The clinical potential and broad therapeutic applicability of P7C3 warrants much needed investigation into whether these remedial effects can be replicated in the clinic. P7C3 may serve as an important step forward in the design, understanding, and implementation of pharmacotherapies for treating patients with TBI. This article is part of the Special Issue entitled “Novel Treatments for Traumatic Brain Injury”.

Original languageEnglish (US)
Pages (from-to)268-282
Number of pages15
JournalNeuropharmacology
Volume145
DOIs
StatePublished - Feb 1 2019

Fingerprint

Neurogenesis
Nicotinamide Phosphoribosyltransferase
Biological Availability
Traumatic Brain Injury
Therapeutics
Survival Rate
Pharmacokinetics
Public Health
Neurons
Drug Therapy
Wounds and Injuries
Research
Pharmaceutical Preparations

Keywords

  • NAD
  • NAMPT
  • Neurogenesis
  • Neuroprotection
  • P7C3
  • Traumatic brain injury

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. / Blaya, Meghan O.; Wasserman, Joseph M.; Pieper, Andrew A.; Sick, Thomas J.; Bramlett, Helen; Dalton Dietrich, W.

In: Neuropharmacology, Vol. 145, 01.02.2019, p. 268-282.

Research output: Contribution to journalReview article

Blaya, Meghan O. ; Wasserman, Joseph M. ; Pieper, Andrew A. ; Sick, Thomas J. ; Bramlett, Helen ; Dalton Dietrich, W. / Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. In: Neuropharmacology. 2019 ; Vol. 145. pp. 268-282.
@article{bd8d92f9ee7249af86d4f9c55da7cf29,
title = "Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury",
abstract = "Traumatic brain injury (TBI) is a significant public health problem around the world. A promising area of research is the characterization of small, drug-like molecules that have potent clinical properties. One pharmacotherapeutic agent in particular, an aminopropyl carbazole called P7C3, was discovered using an in vivo screen to identify new agents that augmented the net magnitude of adult hippocampal neurogenesis. P7C3 greatly enhanced neurogenesis by virtue of increasing survival rates of immature neurons. The potent neuroprotective efficacy of P7C3 is likely due to enhanced nicotinamide phosphoribosyltransferase (NAMPT) activity, which supports critical cellular processes. The scaffold of P7C3 was found to have favorable pharmacokinetic properties, good bioavailability, and was nontoxic. Preclinical studies have shown that administration of the P7C3-series of neuroprotective compounds after TBI can rescue and reverse detrimental cellular events leading to improved functional recovery. In several TBI models and across multiple species, P7C3 and its analogues have produced significant neuroprotection, axonal preservation, robust increases in the net magnitude of adult neurogenesis, protection from injury-induced LTP deficits, and improvement in neurological functioning. This review will elucidate the exciting and diverse therapeutic findings of P7C3 administration in the presence of a complex and multifactorial set of cellular and molecular challenges brought forth by experimental TBI. The clinical potential and broad therapeutic applicability of P7C3 warrants much needed investigation into whether these remedial effects can be replicated in the clinic. P7C3 may serve as an important step forward in the design, understanding, and implementation of pharmacotherapies for treating patients with TBI. This article is part of the Special Issue entitled “Novel Treatments for Traumatic Brain Injury”.",
keywords = "NAD, NAMPT, Neurogenesis, Neuroprotection, P7C3, Traumatic brain injury",
author = "Blaya, {Meghan O.} and Wasserman, {Joseph M.} and Pieper, {Andrew A.} and Sick, {Thomas J.} and Helen Bramlett and {Dalton Dietrich}, W.",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2018.09.024",
language = "English (US)",
volume = "145",
pages = "268--282",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury

AU - Blaya, Meghan O.

AU - Wasserman, Joseph M.

AU - Pieper, Andrew A.

AU - Sick, Thomas J.

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Traumatic brain injury (TBI) is a significant public health problem around the world. A promising area of research is the characterization of small, drug-like molecules that have potent clinical properties. One pharmacotherapeutic agent in particular, an aminopropyl carbazole called P7C3, was discovered using an in vivo screen to identify new agents that augmented the net magnitude of adult hippocampal neurogenesis. P7C3 greatly enhanced neurogenesis by virtue of increasing survival rates of immature neurons. The potent neuroprotective efficacy of P7C3 is likely due to enhanced nicotinamide phosphoribosyltransferase (NAMPT) activity, which supports critical cellular processes. The scaffold of P7C3 was found to have favorable pharmacokinetic properties, good bioavailability, and was nontoxic. Preclinical studies have shown that administration of the P7C3-series of neuroprotective compounds after TBI can rescue and reverse detrimental cellular events leading to improved functional recovery. In several TBI models and across multiple species, P7C3 and its analogues have produced significant neuroprotection, axonal preservation, robust increases in the net magnitude of adult neurogenesis, protection from injury-induced LTP deficits, and improvement in neurological functioning. This review will elucidate the exciting and diverse therapeutic findings of P7C3 administration in the presence of a complex and multifactorial set of cellular and molecular challenges brought forth by experimental TBI. The clinical potential and broad therapeutic applicability of P7C3 warrants much needed investigation into whether these remedial effects can be replicated in the clinic. P7C3 may serve as an important step forward in the design, understanding, and implementation of pharmacotherapies for treating patients with TBI. This article is part of the Special Issue entitled “Novel Treatments for Traumatic Brain Injury”.

AB - Traumatic brain injury (TBI) is a significant public health problem around the world. A promising area of research is the characterization of small, drug-like molecules that have potent clinical properties. One pharmacotherapeutic agent in particular, an aminopropyl carbazole called P7C3, was discovered using an in vivo screen to identify new agents that augmented the net magnitude of adult hippocampal neurogenesis. P7C3 greatly enhanced neurogenesis by virtue of increasing survival rates of immature neurons. The potent neuroprotective efficacy of P7C3 is likely due to enhanced nicotinamide phosphoribosyltransferase (NAMPT) activity, which supports critical cellular processes. The scaffold of P7C3 was found to have favorable pharmacokinetic properties, good bioavailability, and was nontoxic. Preclinical studies have shown that administration of the P7C3-series of neuroprotective compounds after TBI can rescue and reverse detrimental cellular events leading to improved functional recovery. In several TBI models and across multiple species, P7C3 and its analogues have produced significant neuroprotection, axonal preservation, robust increases in the net magnitude of adult neurogenesis, protection from injury-induced LTP deficits, and improvement in neurological functioning. This review will elucidate the exciting and diverse therapeutic findings of P7C3 administration in the presence of a complex and multifactorial set of cellular and molecular challenges brought forth by experimental TBI. The clinical potential and broad therapeutic applicability of P7C3 warrants much needed investigation into whether these remedial effects can be replicated in the clinic. P7C3 may serve as an important step forward in the design, understanding, and implementation of pharmacotherapies for treating patients with TBI. This article is part of the Special Issue entitled “Novel Treatments for Traumatic Brain Injury”.

KW - NAD

KW - NAMPT

KW - Neurogenesis

KW - Neuroprotection

KW - P7C3

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85058448884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058448884&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.09.024

DO - 10.1016/j.neuropharm.2018.09.024

M3 - Review article

C2 - 30236963

AN - SCOPUS:85058448884

VL - 145

SP - 268

EP - 282

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -